Life Science Investing Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome
Life Science Investing Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Life Science Investing Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4
Life Science Investing Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome
Life Science Investing Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting
Life Science Investing Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome
Life Science Investing Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635
Locksley Confirms Continuous High Grade Mineralized Silver Corridor at its Mojave Project in California
Homerun Resources Inc. Closes Acquisition of Additional Mineral Rights in the Santa Maria Eterna Silica Sand District
Rio Silver Highlights High-Grade Silver up to 6.26 g/t Au and 991 g/t Ag over 0.70 metres at Maria Norte and Advances a Clear Near-Term Development Path in Peru
